Ewing Sarcoma
Ewing Sarcoma (ES)
nanovalentpharma.comCrawled Oct 15, 2026
Ewing Sarcoma (ES)
The page describes glioblastoma (GBM) as the most common aggressive malignant grade 4 tumor, with a poor prognosis and limited treatment options. It says glioblastoma thrives in the brain’s microenvironment.
Reimagine the Power ofTargeted Therapies. Significantly Improving Upon the Delivery, Safety and Performance of Both Existing and Developing Cancer Therapeutics; Progressing beyond ADCs and Untargeted Nanoparticles.
Ovarian cancer, a complex disease with multiple subtypes, is the fifth leading cause of cancer-related deaths among women in the United States and the third most commonly diagnosed gynecological cancer in the world.
NanoValent Pharmaceuticals says its platform preferentially delivers cytotoxic drugs to cancer cells while sparing healthy cells and tissues, and lowers systemic cytotoxic doses to minimize morbidity. Its nano-ADCs include Targeted Nanospheres (nADC/TNS).
Targeting Hard to Treat Cancers. Validated targets include CD99 (MIC2) and CD276 (B7H3).
The page is a blog template created by Superb Addons and includes instructions for editing its content or the blog template.
NanoValent Pharmaceuticals' upcoming and most recent events and presentations.
NanoValent reported presenting data at AACR in Chicago in 2025 on enhancing GBM therapy with tumor-targeted nanoparticles, and in San Diego in 2024 on tumor-targeted nanoparticles for cancer therapy.
NanoValent Pharmaceuticals says it is translating its science into targeted therapies and addressing barriers to treatment for patients with hard-to-treat cancers.
NanoValent Pharmaceuticals says it is committed to addressing unmet medical needs in oncology and hematology through therapeutic approaches for hard-to-treat cancers.
The page presents available job opportunities.
NanoValent Pharmaceuticals addresses unmet medical needs in oncology and hematology by developing therapeutic approaches for hard-to-treat cancers, with the potential to improve patient outcomes.
NanoValent Pharmaceuticals’ Scientific Advisory Board guides R&D activities and development of targeted anticancer agents. Its members are academics and experts in oncology, hematology, and pharmaceutical R&D.
NanoValent Pharmaceuticals works with a variety of US-based and international academic and industry partners.
NanoValent Pharmaceuticals lists its corporate address as 351-B Evergreen Dr., Bozeman, MT 59715, and its phone as +1 (406) 586 8420. It also says it is a member of the ADC Directory.
NanoValent Pharmaceuticals lists its corporate address as 351-B Evergreen Dr., Bozeman, MT 59715, and its phone number as +1 (406) 586 8420. It is a member of the ADC Directory.
The page explains that cookies are small text files stored on a device and says they help the company understand visitor interactions, improve website performance, and deliver personalized content.
The NanoValent Pharmaceuticals Privacy Notice explains how the company treats personal information submitted through the website and how it may combine that information with other information about users.
The privacy policy describes how the company collects, uses, and protects personal information, including information provided when users create an account, make a purchase, or contact support.
NanoValent Pharmaceuticals says it maintains the website for personal use, education, and communication, and that access and use are subject to its terms, privacy notice, and applicable laws.
The terms say that users who access and use the website agree to them and grant permission to temporarily download one copy of the materials.